NOP16 and colorectal carcinoma: Furthermore, consistent with these results, blocking CXCR2 using navarixin, a CXCR2 inhibitor, in CRC cells impaired HSPC111, CXCR2 and EMT-associated genes expression and cell migration of CRC cells as well (Fig. 7H–J and Supplementary Fig. S5D).